Spelling suggestions: "subject:"phase I"" "subject:"chase I""
31 |
Essais cliniques de recherche de dose en oncologie : d'un schéma d'essai permettant l'inclusion continue à l’utilisation des données longitudinales de toxicité / Dose-finding clinical trials in oncology : from continuous enrolment, to the integration of repeated toxicity measurementsDoussau de Bazignan, Adélaïde 31 March 2014 (has links)
L’objectif des essais de phase I en oncologie est d’identifier la dose maximale tolérée (DMT). Le schéma « 3+3 » nécessite d’interrompre les inclusions en attendant l’évaluation d’une cohorte de trois patients pour définir la dose à attribuer aux patients suivants. Les investigateurs d’oncologie pédiatrique ont proposé l’adaptation Rolling 6 pour éviter cette suspension temporaire des inclusions. Dans une étude de simulation, nous avons montré qu’un schéma adaptatif avec attribution des doses basées sur un modèle statistique permettait de pallier ce problème, et identifiait plus fréquemment la DMT. Néanmoins ces trois schémas restent limités pour identifier la DMT, notamment du fait que le critère de jugement est un critère binaire, la survenue de toxicité dose-limitante sur un cycle de traitement. Nous avons proposé un nouveau schéma adaptatif utilisant les données ordinales répétées de toxicité sur l’ensemble des cycles de traitement. La dose à identifier est celle associée au taux de toxicité grave maximal par cycle que l’on juge tolérable. Le grade maximal de toxicité par cycle de traitement, en 3 catégories (grave / modéré / nul), a été modélisé par le modèle mixte à cotes proportionnelles. Le modèle est performant à la fois pour détecter un effet cumulé dans le temps et améliore l’identification de la dose cible, sans risque majoré de toxicité, et sans rallonger la durée des essais. Nous avons aussi étudié l’intérêt de ce modèle ordinal par rapport à un modèle logistique mixte plus parcimonieux. Ces modèles pour données longitudinales devraient être plus souvent utilisés pour l’analyse des essais de phase I étant donné leur pertinence et la faisabilité de leur implémentation. / Phase I dose-finding trials aim at identifying the maximum tolerated dose (MTD). The “3+3” design requires an interruption of enrolment while the evaluation of the previous three patients is pending. In pediatric oncology, investigators proposed the Rolling 6 design to allow for a more continuous enrollment. In a simulation study, we showed that an adaptive dose-finding design, with dose allocation guided by a statistical model not only minimizes accrual suspension as with the rolling 6, and but also led to identify more frequently the MTD. However, the performance of these designs in terms of correct identification of the MTD is limited by the binomial variability of the main outcome: the occurrence of dose-limiting toxicity over the first cycle of treatment. We have then proposed a new adaptive design using repeated ordinal data of toxicities experienced during all the cycles of treatment. We aim at identifying the dose associated with a specified tolerable probability of severe toxicity per cycle. The outcome was expressed as the worst toxicity experienced, in three categories (severe / moderate / no toxicity), repeated at each treatment cycle. It was modeled through a proportional odds mixed model. This model enables to seek for cumulated toxicity with time, and to increase the ability to identify the targeted dose, with no increased risk of toxicity, and without delaying study completion. We also compared this ordinal model to a more parsimonious logistic mixed model.Because of their applicability and efficiency, those models for longitudinal data should be more often used in phase I dose-finding trials.
|
32 |
Energy Reconstruction and high-speed Data Transmission with FPGAs for the Upgrade of the ATLAS Liquid Argon Calorimeter at LHCStärz, Steffen 19 May 2015 (has links)
The Liquid Argon calorimeter of the ATLAS detector at CERN near Geneva is equipped with improved readout and trigger electronics for the operation at higher luminosity LHC in the frame of several upgrades (Phase-0, I, and II). Special attention is given to an early digitisation of detector raw data and their following digital data transmission and processing via FPGAs already for the Level-1 trigger. The upgrades additionally foresee to provide higher spatial granularity information for the Level-1 trigger in order to improve its performance for low momentum single particles at increased collision rates.
The first part of this dissertation contains the development and implementation of a modular detector simulation framework, AREUS, which allows to analyse different filter algorithms for the energy reconstruction as well as their performance with respect to the expected digitised detector raw data. In this detector simulation framework the detailed algorithmic functionality of the FPGAs has been taken into account. Various filter algorithms, especially the Optimal Filter and a Wiener Filter with Forward Correction, are discussed with regard to their performance in energy reconstruction of the future Liquid Argon calorimeter trigger system.
In the second part of this thesis, the high-speed data transfer for the acquisition of the trigger data is being developed. For this purpose, a generic 10 Gigabit Ethernet UDP stack is designed in VHDL, that is currently applied in an ALTERA® Stratix-IV FPGA as part of the readout electronics of a demonstrator setup in the context of the Phase-0 Upgrade. After implementation in a prototype electronics board, data transfer from the detector front-end is realised. A successful test in the demonstrator setup installed in the ATLAS detector verifying the correct transmission of the Liquid Argon calorimeter trigger signals concludes this work. / Das Flüssig-Argon-Kalorimeter des ATLAS-Detektors am CERN bei Genf wird für den Betrieb am LHC mit erhöhter Luminosität im Rahmen mehrerer Upgrades (Phase-0, I und II) mit verbesserter Auslese- und Triggerelektronik ausgestattet. Ein besonderes Augenmerk liegt hierbei auf der frühzeitigen Digitalisierung der Detektorrohdaten und deren folgende digitale Übertragung sowie Verarbeitung mittels FPGAs bereits für den Level-1 Trigger. Die Upgrades sehen zusätzlich vor, dem Level-1 Trigger eine höhere Ortsauflösung bereitzustellen um seine Leistungsfähigkeit der Energierekonstruktion von niedrigenergetischen Teilchen bei erhöhter Kollisionsrate zu verbessern.
Der erste Teil dieser Dissertation beinhaltet die Entwicklung und Umsetzung einer modularen Detektorsimulationsumgebung, AREUS, mit der verschiedene Filteralgorithmen zur Energierekonstruktion sowie deren Performanz in Abhängigkeit der erwarteten digitalisierten Detektorrohdaten analysiert werden können. Dabei wurde in der Simulationsumgebung die Funktionalität der Rechenarithmetik der später verwendeten FPGAs berücksichtigt. Verschiedener Filteralgorithmen, im Besonderen der Optimal Filter und ein Wiener Filter mit Korrekturglied, werden im Hinblick auf ihre Performanz der Energierekonstruktion für das zukünftige Triggersystem des Flüssig-Argon-Kalorimeters diskutiert.
Der zweite Teil dieser Arbeit beschäftigt sich mit der Hochgeschwindigkeitsdatenübertragung zur Erfassung von Triggerdaten. Zu diesem Zweck wird ein generischer 10 Gigabit Ethernet UDP Stack in VHDL entworfen, der als Teil der Ausleseelektronik eines Demonstrator-Testaufbaus im Rahmen des Phase-0 Upgrades in einem ALTERA® Stratix-IV FPGA aktuell zum Einsatz kommt. Nach Implementierung in einem Prototypen einer Auslesekarte konnte ein Transfer von Detektordaten realisiert werden. Eine Überprüfung am Demonstrator-Testaufbau, welcher im ATLAS Detektor installiert ist, schließt diese Dissertation ab. Sie hat eine korrekte Übertragung von Triggersignalen des Flüssig-Argon-Kalorimeters erfolgreich bestätitgt.
|
33 |
Estudo clínico fase I/II de segurança e eficácia de um medicamento inovador para tratamento de litíase renal / A Phase I/II clinical trial for evaluating safety and efficacy of an innovative medicine to nephrolithiasis treatmentLorencini, Daniela Aparecida 30 May 2019 (has links)
A nefrolitíase é uma doença comum e recorrente com prevalência mundial variando de 5 a 20%, com pico de incidência entre a 3ª e 4ª década de vida e com maior prevalência em homens (3:1), frequentemente associado a atendimento de urgência. O tratamento da litíase ocorre em duas fases. Inicialmente, no episódio agudo de dor pela passagem do cálculo pelas vias urinárias, cujo objetivo terapêutico é o alívio da dor e a expulsão do cálculo. Para aqueles doentes com cálculos de repetição, o objetivo terapêutico será o de reduzir a formação de novos cálculos. Para ambos os objetivos, o arsenal terapêutico disponível é limitado. Estudos pré-clínicos com o Extrato Padronizado de C. langsdorffi - EPC-AF® (Apis-Flora, Ribeirão Preto, Brasil), um composto vegetal extraído da bioflora nacional, mostraram perfil de segurança e eficácia deste composto como potencial medicamento para o tratamento da litíase renal. Desta forma, o objetivo deste estudo foi o de avaliar o perfil de segurança em humanos e eficácia preliminar do EPC-AF®. Foi realizado um estudo clínico fase I/IIa, randomizado, duplo-cego, comparado com placebo, de dose única de forma ascendente. As doses utilizadas foram de 175 mg, 350 mg,700 mg, 1,4 g e 2,8 g administradas por via oral em dose única após jejum de 12h. Foram estudados grupos de 6 voluntários sadios por dose. Em cada grupo, 4 voluntários receberam de forma randomizada e cega o EPC-AF® e 2 voluntários placebo. O escalonamento para doses mais altas foi feito após a comprovação de que não houve eventos adversos com a dose previamente usada. No total, 30 voluntários sadios foram estudados na Unidade de Pesquisa Clínica do HCFMRP-USP. Foram coletados dados clínicos e laboratoriais para segurança, com destaque para toxicidade renal, onde foram estudados variação das concentrações urinárias de NGAL (neutrophil gelatinaseassociated lipocalin), NAG (N-acetyl-beta-D-glucosaminidase), KIM-1 (Kidney injury molecule-1) e alfa-1-microglobulina, além da dosagem sérica de cistatina C, um marcador da taxa de filtração glomerular. Os dados de eficácia preliminar foramcentrados na análise do perfil bioquímico urinário (pH, cálcio, citrato, oxalato, ácido úrico, magnésio e fosforo) em amostras de urina de 24h, coletadas antes e imediatamente após o uso de EPC-AF® ou placebo. Os resultados obtidos mostraram que o EPC-AF® é seguro nas doses de 175 a 2,8 g por via oral. Não foi observada variações significativas das concentrações de 24h dos principais componentes facilitadores ou inibidores da formação de cálculos urinários / Nephrolithiasis is a common and recurrent disease with a worldwide prevalence varying from 5 to 20%, with a incidence peak between the 3rd and 4th decade of life and with a higher prevalence in men than women (3: 1), often associated with urgent care. The treatment of lithiasis occurs in two phases. Firstly, in the acute episode of pain by the passage of the calculus through the urinary tract, whose therapeutic objective is to relieve pain and expel the stone. For those patients with recurrent stones the therapeutic goal will be reducing the formation of new stones. For both objectives, the available therapeutic arsenal is limited. Preclinical studies with C. langsdorffi standard extract (EPC-AF®, Apis-Flora, Ribeirão Preto, Brazil), an herbal compound extracted from a Brazilian native plant, showed a safety and efficacy profile of this compound as a potential drug for the treatment of renal lithiasis. Thus, the objective of this study was to evaluate the safety profile and the preliminary efficacy of EPC-AF® in healthy volunteers. A phase I/IIa clinical trial, randomized, double-blinded, placebocontrolled single-ascending dose was conducted. The doses used were 175 mg, 350 mg, 700 mg, 1.4 g and 2.8 g administered orally in a single dose after 12 h fasting. Groups of 6 healthy volunteers per dose were studied. In each group, 4 volunteers randomly and blindly received EPC-AF® and 2 volunteers received placebo. The escalation to higher doses was done after the confirmation that there were no adverse events with the dose previously used. In total, 30 healthy volunteers were studied on the General Clinical Research Centre of local teaching Hospital. Clinical and laboratory data were collected for safety, with emphasis on renal toxicity, where urinary concentrations of NGAL (neutrophil gelatinase-associated lipocalin), NAG (N-acetylbeta-D-glucosaminidase), KIM-1 (Kidney injury molecule-1) and alpha-1-microglobulin were measured, in addition to serum cystatin C, a marker of the glomerular filtration rate. Preliminary efficacy data were centered on urinary biochemical profile analysis (pH, calcium, citrate, oxalate, uric acid, magnesium and phosphorus) in 24-hour urinesamples collected before and immediately after use of EPC-AF® or placebo. The results showed that EPC-AF® is safe in doses of 175 to 2.8 g orally. No significant variations in 24-h concentrations of the major components facilitating or inhibiting the formation of urinary stones were observed
|
34 |
The effect of sulforaphane on oxidative stress and biotransformation in HepaRG cells / A. Crous.Crous, Ané January 2013 (has links)
Sulforaphane is an isothiocyanate found in high concentrations in cruciferous vegetables like broccoli. Sulforaphane has received much attention due to the evidence that it inhibits phase I carcinogen-bioactivating enzymes and/or induces phase II antioxidant enzymes as well as metallothioneins (MTs) (Perocco et al., 2006; Clarke et al., 2008; Yeh & Yen, 2009). Since MTs and antioxidant enzymes are involved in the scavenging of reactive oxygen species (ROS), the question was raised whether sulforaphane can provide protection against increased oxidative stress and if sulforaphane exposure of a human hepatocellular carcinoma cell line, like HepaRG cells, will have a negative impact on phase I and II biotransformation in these cells. Oxidative stress was exogenously induced in HepaRG cells with tert- Butyl hydroperoxide (t-BHP). Phase I and phase II biotransformation pathways were assessed with caffeine, paracetamol, aspirin, sodium benzoate, and paraaminobenzoic acid, respectively, as probe substances. Through the use of a liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS/MS) assay, the biotransformation of caffeine in phase I and the formation of paracetamol, aspirin, sodium benzoate and para-aminobenzoic acid conjugates in phase II were investigated. This involved elucidating the time it took for the whole probe to be completely biotransformed during phase I biotransformation and the unique conjugates formed during phase II biotransformation in HepaRG cells.
The optimal t-BHP concentration and exposure time in HepaRG cells were standardized with a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. LC-ESI-MS/MS assays to monitor phase I and phase II biotransformation were optimized and validated. The optimal sulforaphane concentration and exposure time in HepaRG cells were standardized with a MTT assay. To evaluate the possible protective effect of sulforaphane against oxidative stress, HepaRG cells were pre-incubated with sulforaphane followed by the induction of oxidative stress with t-BHP and the quantification of the amount of viable cells with a MTT assay. To investigate the effect of sulforaphane on phase I and phase II biotransformation pathways, HepaRG cells were first pre-incubated with sulforaphane followed by the addition of a specific probe substance and the assessment of the biotransformation of the probe with a LC-ESI-MS/MS assay.
The results partially supported the hypothesis of the study that sulforaphane will protect HepaRG cells against oxidative stress without negatively influencing phase I and phase II biotransformation. The results indicated that sulforaphane provided partial protection against t-BHP induced oxidative stress and had no effect on phase II paracetamol biotransformation in HepaRG cells. / Thesis, MSc (Biochemistry), North-West University, Potchefstroom Campus, 2013.
|
35 |
The effect of sulforaphane on oxidative stress and biotransformation in HepaRG cells / A. Crous.Crous, Ané January 2013 (has links)
Sulforaphane is an isothiocyanate found in high concentrations in cruciferous vegetables like broccoli. Sulforaphane has received much attention due to the evidence that it inhibits phase I carcinogen-bioactivating enzymes and/or induces phase II antioxidant enzymes as well as metallothioneins (MTs) (Perocco et al., 2006; Clarke et al., 2008; Yeh & Yen, 2009). Since MTs and antioxidant enzymes are involved in the scavenging of reactive oxygen species (ROS), the question was raised whether sulforaphane can provide protection against increased oxidative stress and if sulforaphane exposure of a human hepatocellular carcinoma cell line, like HepaRG cells, will have a negative impact on phase I and II biotransformation in these cells. Oxidative stress was exogenously induced in HepaRG cells with tert- Butyl hydroperoxide (t-BHP). Phase I and phase II biotransformation pathways were assessed with caffeine, paracetamol, aspirin, sodium benzoate, and paraaminobenzoic acid, respectively, as probe substances. Through the use of a liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS/MS) assay, the biotransformation of caffeine in phase I and the formation of paracetamol, aspirin, sodium benzoate and para-aminobenzoic acid conjugates in phase II were investigated. This involved elucidating the time it took for the whole probe to be completely biotransformed during phase I biotransformation and the unique conjugates formed during phase II biotransformation in HepaRG cells.
The optimal t-BHP concentration and exposure time in HepaRG cells were standardized with a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. LC-ESI-MS/MS assays to monitor phase I and phase II biotransformation were optimized and validated. The optimal sulforaphane concentration and exposure time in HepaRG cells were standardized with a MTT assay. To evaluate the possible protective effect of sulforaphane against oxidative stress, HepaRG cells were pre-incubated with sulforaphane followed by the induction of oxidative stress with t-BHP and the quantification of the amount of viable cells with a MTT assay. To investigate the effect of sulforaphane on phase I and phase II biotransformation pathways, HepaRG cells were first pre-incubated with sulforaphane followed by the addition of a specific probe substance and the assessment of the biotransformation of the probe with a LC-ESI-MS/MS assay.
The results partially supported the hypothesis of the study that sulforaphane will protect HepaRG cells against oxidative stress without negatively influencing phase I and phase II biotransformation. The results indicated that sulforaphane provided partial protection against t-BHP induced oxidative stress and had no effect on phase II paracetamol biotransformation in HepaRG cells. / Thesis, MSc (Biochemistry), North-West University, Potchefstroom Campus, 2013.
|
36 |
Ensaios farmacológicos clínicos de fases I e II com o hidrogel obtido a partir do extrato etanólico bruto da casca de Anacardium occidentale Linn. no tratamento da acne vulgar. / Pharmacological clinical trial phase I and II with the hydrogel obtained from the ethanol crude extract of the bark of Anacardium occidentale Linn. in the treatment of acne vulgaris.Sobral Filho, Jader Freire 30 November 2010 (has links)
Made available in DSpace on 2015-05-14T13:00:15Z (GMT). No. of bitstreams: 1
arquivototal.pdf: 849258 bytes, checksum: 8375e090134f0298c00baace065c84c1 (MD5)
Previous issue date: 2010-11-30 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES / The acne vulgaris is the most prevalent dermatologic disease of teen age. Many
drugs are used in the treatment of acne but it is necessary a drug with safety
and efficacy. The gel extracted from the bark Anacardium occidentale Linn. is
indicated for topical treatment of inflammatory diseases. The purpose of this
study was to evaluate the clinical pharmacology of this formulation in healthy
volunteers. For this, a non-randomized open clinical trial was conducted with 40
healthy volunteers (22 female and 18 male), who administered the topical gel in
their faces during 3 weeks. The volunteers were included in the study only when
considered healthy after clinical assessment, physical examination and
laboratory tests which preceded the study. The laboratory tests included:
hematological, biochemical and serological analysis. The clinical and laboratory
evaluation were repeated after the first week and at the end of the third week
after the last administration. This gel was well tolerated by the 40 volunteers,
and it has showed no adverse events. The clinical and laboratory data
assessed before, during and after the test showed no signals of toxicity in
various organs and systems evaluated, confirming the safety of the preparation
for use in trials of therapeutic efficacy. A randomized, investigator-blinded,
controlled study was conducted to evaluate the efficacy and safety of gel
obtained from the bark of Anacardium occidentale Linn. (AO) versus adapalene
gel 0,1%. Subjects were assigned randomly to receive either adapaleno gel
0,1% or AO once daily for 12 weeks. A total of 43 subjects with mild to
moderate acne vulgaris (AV) were enrolled. Adapalene gel 0,1% was
significantly superior to AO in noninflammatory lesion counts (p<0,005). But, the
efficacy was statistically similar between two group for inflammatory lesion
counts and in the reduction of total lesion count (p<1,0). Treatment-related
adverse events were mostly mild-to-moderate in the group of adapaleno gel
0,1%. But in the group of AO no adverse events was seen. The results of this
study show that Adapalene 0,1% gel was superior to AO in noninflammatory
lesions of AV but similar in inflammatory and total counts lesions while AO was
superior in safety and tolerability profile to adapaleno 0,1% gel. / A acne vulgar é a dermatose mais prevalente entre os adolescentes apresenta
um grande impacto psico-social. Várias classes de fármacos são utilizadas no
tratamento da AV, porém ainda não há um fármaco que seja ao mesmo tempo
seguro e eficaz. O objetivo desse estudo foi avaliar a farmacologia clínica do o
hidrogel obtido a partir do extrato etanólico bruto da casca de Anacardium
occidentale Linn. (AO) em voluntários saudáveis. Para atingir este objetivo
realizou-se um ensaio clínico não aleatório, aberto, com 40 voluntários sadios,
sendo 22 mulheres e 18 homens, os quais aplicaram o gel na face uma vez ao
dia, durante três semanas. Os voluntários foram incluídos no estudo somente
após serem considerados saudáveis, depois de avaliações clínica e laboratorial
que antecederam o estudo. A avaliação laboratorial consistiu de análise
hematológica, bioquímica e sorológica. As avaliações clínica e laboratorial
foram repetidas após a primeira semana e no final do tratamento, na terceira
semana do estudo. A aplicação tópica do gel deste fitoterápico foi bem tolerada
pelos 40 voluntários sadios os quais não apresentaram efeitos adversos. Os
exames clínicos e laboratoriais realizados antes, durante e após o ensaio não
evidenciaram sinais de toxidade na pele e nem nos diversos órgãos e sistemas
avaliados, demonstrando segurança do produto, sendo estes resultados
promissores para a realização de ensaios de eficácia terapêutica. Um ensaio
clínico farmacológico, randomizado, duplo cego, controlado foi realizado para
avaliar a eficácia e segurança (ensaio de fase II) do hidrogel obtido a partir do
extrato etanólico bruto da casca de AO comparando-o com adapaleno gel a
0,1%. Os indivíduos foram designados randomicamente a receber o gel de AO
ou o adapaleno gel a 0,1% diariamente durante 12 semanas. Foi recrutado um
grupo total de 43 indivíduos com acne vulgar (AV) leve e moderada. O
adapaleno gel a 0,1% foi significativamente superior ao gel de AO na contagem
das lesões não inflamatórias (cômedos). Contudo, para as lesões de natureza
inflamatória da AV não houve diferenças estatisticamente significativas entre os
dois grupos tratados. Resultados semelhantes, foram obtidos, em relação à
redução na contagem total das lesões da AV, houve 42,7% de redução na
contagem total das lesões da AV com AO e 43,1% para o gel de adapaleno a
0,1 %, não havendo diferença estatística entre os grupos tratados. Os efeitos
adversos relatados foram, em sua maioria, de leves a moderados no grupo que
utilizou o adapaleno e não ocorreu nenhum evento adverso no grupo tratado
com o gel da AO. Os resultados desse estudo mostram que tanto o adapaleno
gel como o AO foram eficazes no tratamento da AV, sendo o gel de adapaleno
a 0,1% superior ao gel de AO para as lesões não inflamatórias da AV, porém,
os dois produtos foram estatisticamente semelhantes para a redução na
contagem total das lesões e naquelas de natureza inflamatória. O perfil de
segurança e tolerabilidade foi superior para AO.
|
37 |
RBP (Revlimid®, Bendamustin und Prednisolon) weist ein vorteilhaftes Sicherheits- und Wirksamkeitsprofil bei rezidiviertem/refraktärem Multiplem Myelom auf: Endergebnisse einer klinischen Phase I-Studie OSHO – #077Heyn, Simone 11 April 2018 (has links)
Hintergrund: Während die Monotherapie mit Lenalidomid (Revlimid®) bei der Behandlung von rezidivierten/refraktären Patienten mit Multiplem Myelom (MM) bewährt ist, werden Kombinationstherapien mit Lenalidomid immer noch untersucht. In der vorliegenden Dosisfindungsstudie wurde eine Kombinationstherapie bestehend aus Lenalinomid, Bendamustin und Prednisolon (RBP) an Patienten mit fortgeschrittenem MM getestet.
Methoden: Die erste Patientenkontrollgruppe erhielt eine Anfangsdosis Lenalidomid von 10 mg/d d1-21, Bendamustin von 60 mg/m²/d d1-2 und Prednisolon von 100 mg/d d1-4.
Weitere Patientengruppen (jeweils 3-6 Personen) erhielten in Stufen eine steigende Lenalidomid-Dosis von 15, 20 sowie 25 mg und nach Erreichen von 25 mg Lenalidomid eine ansteigende Dosis Bendamustin von zunächst 60 mg/m² und dann 75 mg/m².
Ergebnisse: 21 Patienten (jeweils 3 in den ersten drei Dosierungsstufen und jeweils 6 in den beiden letzten Dosierungsstufen) wurden in dieser Phase-I-Studie eingeschlossen. Alle Patienten erhielten mindestens 2 Zyklen der Therapie.
Zwei Patienten entwickelten eine dosislimitierende Hämatotoxizität, ein Patient bei 25 mg/d Lenalidomid in Kombination mit 60 mg/m² Bendamustin und ein Patient in der höchsten Dosierungsstufe (25 mg/d Lenalidomid in Kombination mit 75 mg/m² Bendamustin). Die maximal tolerable Dosis wurde nicht erreicht. 16 Patienten (76%) sprachen nach mindestens zwei Zyklen RBP mit 1 sCR, 1 nCR, 5 VGPR und 9 RP an. Nach einer medianen Beobachtungszeit von 16 Monaten lag das PFS nach 18 Monaten bei 48% und OS bei 64%.
Schlussfolgerung: RBP mit einer Dosis von 25 mg Lenalidomid (d 1-21) und 75 mg/m² Bendamustin (d 1-2) ist gut verträglich bei Patienten mit rezidiviertem/refraktärem MM.:Zusammenfassung II
Abstract III
Inhaltsverzeichnis IV
Abbildungsverzeichnis VI
Tabellenverzeichnis VII
Abkürzungsverzeichnis VIII
1 Einleitung 1
1.1 Multiples Myelom 1
1.1.1 Terminologie 1
1.1.2 Epidemiologie 1
1.1.3 Ätiologie 2
1.1.4 Pathogenese 2
1.1.5 Klinik 3
1.1.5.1 Symptome des Skelettsystems 3
1.1.5.2 Anämiesymptome 3
1.1.5.3 Nierenbeteiligung 4
1.1.5.4 Infektionen 4
1.1.6 Diagnostik 5
1.1.6.1 Labordiagnostik 5
1.1.6.1.1 Myelomproteindiagnostik 5
1.1.6.1.2 Blutbild 6
1.1.6.1.3 Nierenwerte 6
1.1.6.1.4 ß2-Mikroglobulin 6
1.1.6.1.5 Knochenmarkdiagnostik 7
1.1.6.1.6 Knochenmarkmorphologie 7
1.1.6.1.7 Durchflusszytometrie 7
1.1.6.1.8 Zytogenetik 7
1.1.6.2 Radiologische Diagnostik 8
1.1.7 Diagnosekriterien, Differentialdiagnose, Klassifikation und Stadieneinteilung 9
1.2 Therapie 12
1.2.1 Konventionelle Chemotherapie 12
1.2.2 Neue Substanzen 13
1.2.2.1 Immunmodulatorische Substanzen 13
1.2.2.1.1 Thalidomid 13
1.2.2.1.2 Lenalidomid 14
1.2.2.1.3 Pomalidomid 14
1.2.2.2 Proteasom-Inhibitoren 15
1.2.2.2.1 Bortezomib 15
1.2.2.2.2 Carfilzomib 15
1.2.2.2.3 Ixazomib 16
1.2.2.3 HDAC-Inhibitoren 16
1.2.2.4 Monoklonale Antikörper 16
1.2.2.4.1 Daratumomab 17
1.2.2.4.2 Elotuzumab 17
1.2.3 Transplantationen 17
1.2.3.1 Autologe Stammzelltransplantation 17
1.2.3.2 Allogene Stammzelltransplantation 18
1.3 Zielstellung der Arbeit 19
2 Material und Methoden 21
2.1 Patienten 21
2.1.1 Einschlusskriterien 21
2.1.2 Ausschlusskriterien 23
2.2 Studiendesign 24
2.3 Behandlungsprotokoll 25
2.4 Definition des Therapieansprechens 26
2.5 Bestimmung der Therapieeffektivität und Toxizität 26
2.6 Statistische Methoden 27
3 Ergebnisse 28
3.1 Patientencharakteristika 28
3.2 Dosiseskalation 30
3.3 Remission und Überleben 31
3.4 Toxizität 34
4 Diskussion 36
Literaturverzeichnis 40
Erklärung über den Anteil an der Promotionsarbeit 51
Erklärung über die eigenständige Abfassung der Arbeit 52
Danksagung 53
|
38 |
Bayesian methods for borrowing information in clinical drug developmentGünhan, Burak Kürsad 07 December 2020 (has links)
No description available.
|
39 |
Développement d'une méthode de recherche de dose modélisant un score de toxicité pour les essais cliniques de phase I en OncologieEzzalfani Gahlouzi, Monia 02 October 2013 (has links) (PDF)
Le but principal d'un essai de phase I en oncologie est d'identifier, parmi un nombre fini de doses, la dose à recommander d'un nouveau traitement pour les évaluations ultérieures, sur un petit nombre de patients.Le critère de jugement principal est classiquement la toxicité. Bien que la toxicité soit mesurée pour différents organes sur une échelle gradée, elle est généralement réduite à un indicateur binaire appelé "toxicité dose-limitante" (DLT). Cette simplification très réductrice est problématiqu, en particulier pour les thérapies, dites "thérapies ciblées", associées à peu de DLTs.Dans ce travail, nous proposons un score de toxicité qui résume l'ensemble des toxicités observées chez un patient. Ce score, appelé TTP pour Total Toxicity Profile, est défini par la norme euclidienne des poids associés aux différents types et grades de toxicités possibles. Les poids reflètent l'importance clinique des différentes toxicités.\\ Ensuite, nous proposons la méthode de recherche de dose, QLCRM pour Quasi-Likelihood Continual Reassessment Method, modélisant la relation entre la dose et le score de toxicité TTP à l'aide d'une régression logistique dans un cadre fréquentiste.A l'aide d'une étude de simulation, nous comparons la performance de cette méthode à celle de trois autres approches utilisant un score de toxicité : i) la méthode de Yuan et al. (QCRM) basée sur un modèle empirique pour estimer, dans un cadre bayésien, la relation entre la dose et le score, ii) la méthode d'Ivanova et Kim (UA) dérivée des méthodes algorithmiques et utilisant une régression isotonique pour estimer la dose à recommander en fin d'essai, iii) la méthode de Chen et al. (EID) basée sur une régression isotonique pour l'escalade de dose et l'identification de la dose à recommander. Nous comparons ensuite ces quatre méthodes utilisant le score de toxicité aux méthodes CRM basées sur le critère binaire DLT. Nous étudions également l'impact de l'erreur de classement des grades pour les différentes méthodes, guidées par le score de toxicité ou par la DLT.Enfin, nous illustrons le processus de construction du score de toxicité ainsi que l'application de la méthode QLCRM dans un essai réel de phase I. Dans cette application, nous avons utilisé une approche Delphi pour déterminer avec les cliniciens la matrice des poids et le score de toxicité jugé acceptable.Les méthodes QLCRM, QCRM, UA et EID présentent une bonne performance en termes de capacité à identifier correctement la dose à recommander et de contrôle du surdosage. Dans un essai incluant 36 patients, le pourcentage de sélection correcte de la dose à recommander obtenu avec les méthodes QLCRM et QCRM varie de 80 à 90% en fonction des situations. Les méthodes basées sur le score TTP sont plus performantes et plus robustes aux erreurs de classement des grades que les méthodes CRM basées sur le critère binaire DLT.Dans l'application rétrospective, le processus de construction du score apparaît faisable facilement. Cette étude nous a conduits à proposer des recommandations pour guider les investigateurs et faciliter l'utilisation de cette approche dans la pratique.En conclusion, la méthode QLCRM prenant en compte l'ensemble des toxicités s'avère séduisante pour les essais de phase I évaluant des médicaments associés à peu de DLTs a priori, mais avec des toxicités multiples modérées probables.
|
40 |
Advanced Designs of Cancer Phase I and Phase II Clinical TrialsCui, Ye 13 May 2013 (has links)
The clinical trial is the most import study for the development of successful novel drugs. The aim of this dissertation is to develop innovative statistical methods to overcome the three main obstacles in clinical trials: (1) lengthy trial duration and inaccurate maximum tolerated dose (MTD) in phase I trials; (2) heterogeneity in drug effect when patients are given the same prescription and same dose; and (3) high failure rates of expensive phase III confirmatory trials due to the discrepancy in the endpoints adopted in phase II and III trials. Towards overcoming the first obstacle, we originally develop a hybrid design for the time-to-event dose escalation method with overdose control using a normalized equivalent toxicity score (NETS) system. This hybrid design can substantially reduce sample size, shorten study length, and estimate accurate MTD by employing a parametric model and adaptive Bayesian approach. Toward overcoming the second obstacle, we propose a new approach to incorporate patients’ characteristic using our proposed design in phase I clinical trials which considers the personalized information for patients who participant in the trials. To conquer the third obstacle, we propose a novel two-stage screening design for phase II trials whereby the endpoint of percent change in of tumor size is used in an initial screening to select potentially effective agents within a short time interval followed by a second screening stage where progression free survival is estimated to confirm the efficacy of agents. These research projects will substantially benefit both cancer patients and researchers by improving clinical trial efficiency and reducing cost and trial duration. Moreover, they are of great practical meaning since cancer medicine development is of paramount importance to human health care.
|
Page generated in 0.0354 seconds